# Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery

> **NCT02884648** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 35 (estimated)

## Conditions studied

- Malignant Neoplasms of Female Genital Organs
- Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer

## Interventions

- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT02884648
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-11-15
- **Primary completion:** 2027-02-02
- **Final completion:** 2027-02-02
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02884648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02884648, "Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT02884648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*